Share on StockTwits

Health Insurance Innovations (NASDAQ:HIIQ) CEO Michael W. Kosloske sold 14,475 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $11.93, for a total value of $172,686.75. Following the completion of the sale, the chief executive officer now directly owns 100 shares of the company’s stock, valued at approximately $1,193. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Dougherty & Co initiated coverage on shares of Health Insurance Innovations in a research note on Friday, June 6th. They set a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of Health Insurance Innovations from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 20th. They now have a $10.80 price target on the stock. Finally, analysts at Raymond James reiterated a “strong-buy” rating on shares of Health Insurance Innovations in a research note on Monday, April 14th. They now have a $15.00 price target on the stock.

Health Insurance Innovations (NASDAQ:HIIQ) traded down 0.09% on Thursday, hitting $11.63. The stock had a trading volume of 3,117 shares. Health Insurance Innovations has a 52-week low of $9.20 and a 52-week high of $14.08. The stock has a 50-day moving average of $10.50 and a 200-day moving average of $10.74. The company has a market cap of $60.1 million and a price-to-earnings ratio of 219.62.

Health Insurance Innovations (NASDAQ:HIIQ) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.08. On average, analysts predict that Health Insurance Innovations will post $0.39 earnings per share for the current fiscal year.

Health Insurance Innovations, Inc is a developer and administrator of Web-based individual health insurance plans and ancillary products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.